Complement, immune complexes and systemic lupus erythematosus

Revmatologiia

Volumn 35, Issue 1, 1996, Pages 5-23

  Davies, K A ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B RECEPTOR;

ANTIGEN ANTIBODY COMPLEX; COMPLEMENT ACTIVATION; COMPLEMENT DEFICIENCY; COMPLEMENT SYSTEM; ERYTHROCYTE; IMMUNE MEDIATED INJURY; INFECTION SENSITIVITY; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIGEN-ANTIBODY COMPLEX; BACTERIAL INFECTIONS; COMPLEMENT C1R; COMPLEMENT C2; COMPLEMENT SYSTEM PROTEINS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PLASMA EXCHANGE;

EID: 26844457619     PISSN: 13100505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Davies KA, Schifferli JA, Walport MJ. Complement deficiency and immune complex disease. Springer Semin Immunopathol 1994;15:397-416.
2. Madi N, Paccaud J-P, Steiger G, Schifferli JA. Immune adherence of nascent hepatitis B surface antigen-antibody complexes in vivo in humans. Clin Exp Immunol 1989;78:201-6.
3. Haakenstad AO, Mannik M. Saturation of the reticuloendothelial system with soluble immune complexes. J Immunol 1974;112:1939-48.
4. Frank MM, Lawley TJ, Hamburger MI, Brown EJ. Immunoglobulin G Fc receptor-mediated clearance in autoimmune diseases. Ann Intern Med 1983;98:206-18.
5. Lachmann PJ, Walport MJ. Deficiency of the effector mechanisms of the immune response and autoimmunity. In: Whelan J, ed. Autoimmunity and autoimmune disease. Ciba Foundation Symposium # 129. Chichester: Wiley, 1987:149-71.
6. Lobatto S, Daha MR, Breedveld FC et al. Abnormal clearance of soluble aggregates of human immunoglobuin G in patients with systemic lupus erythematosus. Clin Exp Immunol 1988;72:55-9.
7. Lobatto S, Daha MR, Voetman AA et al. Clearance of soluble aggregates of immunoblobulin G in healthy volunteers and chimpanzees. Clin Exp Immunol 1987;68:133.
8. Schifferli JA, Ng YC, Paccaud J-P, Walport MJ. The role of hypocomplementaemia and low erythrocyte complement receptor type 1 numbers in determining abnormal immune complex clearance in humans. Clin Exp Immunol 1989;75:329-35.
9. Kimberly RP, Ralph P. Endocytosis by the mononuclear phagocyte system and autoimmune disease. Am J Med 1983;74:481-93.
10. Atkinson JP, Frank MM. Studies on the in vivo effects of antibody. Interaction of IgM antibody and complement in the immune clearance and destruction of erythrocytes in man. J Clin Invest 1974;54:339-48.
11. Frank MM, Hamburger MI, Lawley TJ, Kimberly RP, Plotz PH. Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med 1979;300:518-23.
12. Hamburger MI, Lawley TJ, Kimberly RP, Plotz PH, Frank MM. A serial study of splenic reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. Arthritis Rheum 1982;25:48.
13. Kimberly RP, Parris TM, Inman RD, McDougal JS. Dynamics of mononuclear phagocyte system Fc receptor function in systemic lupus erythematosus. Relation to disease activity and circulating immune complexes. Clin Exp Immunol 1983;51:261-8.
14. Parris TM, Kimberly RP, Inman RD, McDougal S, Gibofsky A, Christian C. Defective Fc-receptor mediated function of the mononuclear phagocyte system in lupus nephritis. Ann Intern Med 1982;97:526.
15. Valentijn RM, van Overhagen H, Hazevoet HM et al. The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 1985; 28:904-13.
16. Walport MJ, Peters AM, Elkon KB, Pusey C, Lavender JP, Hughes GRV. The splenic extraction ratio of antibody-coated erythrocytes and its response to plasma exchange and pulse methylprednisolone. Clin Exp Immunol 1985;60:465-73.
17. 123I-labelled aggregates of human immunoglobulin G in humans; the effect of splenectomy. Clin Exp Immunol 1989;77:62-6.
18. Davies KA, Walport MJ, Schifferli JA. Maintenance of immune complex solubility and immune adherence In: Rother, Hänsch and Till, eds. The complement system. Heidelberg: Springer-Verlag, 1994.
19. Varga L, Thiry E, Fust G. BSA-anti-BSA immune complexes formed in the presence of serum do not bind to autologous red cells. Immunology 1988;64:381-6.
20. Edberg JC, Kujala GA, Taylor RP. Rapid immune adherence reactivity of nascent, soluble antibody/DNA immune complexes in the circulation. J Immunol 1987; 139:1240-5.
21. Germuth FG. A comparative histologic and immunologic study in rabbits of induced hypersensitivity of the serum sickness type. J Exp Med 1953;97:257-64.
22. Davies KA, Mathieson P, Winearls CG, Rees AJ, Walport MJ. Serum sickness and acute renal failure after streptokinase therapy for myocardial infarction. Clin Exp Immunol 1990;80:83-8.
23. Walport MJ, Ross GD, Mackworth-Young C, Watson JV, Hogg N, Lachmann PJ. Family studies of erythrocyte complement receptor type 1 levels: reduced levels in patients with SLE are acquired, not inherited. Clin Exp Immunol 1985;59:547-54.
24. Wilson JG, Wong WW, Schur PH, Fearon DT. Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus. N Engl J Med 1982;307:981-6.
25. Iida K, Mornaghi R, Nussenzweig V. Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. J Exp Med 1982; 155:1427-38.
26. Giles CM, Davies KA, Walport MJ. In vivo and in vitro C4 molecules on red cells; a correlation of numbers of molecules and haemagglutination. Transfusion 1991; 31:222-8.
27. Giles CM, Davies KA, Loizou S, Moulds JJ, Walport MJ. Quantification of IgG on erythrocytes of patients and normals by radio-ligand assay. Transfus Med 1991; 1:223-8.
28. Hammond A, Rudge AC, Loizou S, Bowcock SJ, Walport MJ. Reduced numbers of complement receptor type 1 on erythrocytes are associated with increased levels of anticardiolipin antibodies. Arthritis Rheum 1989;32. 259-64.
29. Davies KA, Hird V, Stewart S et al. A study of in vivo immune complex formation and clearance in man. J Immunol 1990;144:4613-20.
30. 131I-labelled murine monoclonal antibody from patients' blood by intravenous human anti-murine immunoglobulin antibody. Cancer Res 1990;50:563-7.
31. Paccaud J-P, Carpentier J-L, Schifferli JA. Direct evidence for the clustered nature of complement receptors type 1 on the erythrocyte membrane. J Immunol 1988; 141:3889-94.
32. Cosio FG, Shen XP, Hebert LA. Immune complexes bind preferentially to specific subpopulations of human erythrocytes. Clin Immunol Immunopathol 1990;55: 337-54.
33. Barbota JE, Harrison RA, Backer PJ, Lachmann PJ. An antipeptide antibody that recognizes a neoantigen in the CR1 stump remaining on E after proteolysis. Clin Exp Immunol 1992;87:144-9.
34. Tausk FA, McCutchan JA, Schreiber RD, Spechko P, Gigli I. Deficiency of erythrocyte C3b receptor (CR1) in AIDS and AIDS-related syndromes. Biosci Rep 1986;6:81-6.
35. Jouvin MH, Rozenbaum W, Russo R, Kazatchkine MD. Decreased expression of C3b/C4b receptor (CR1) on erythrocytes in AIDS and AIDS-related syndromes correlates with clinical sub-populations of patients with HIV infection. AIDS 1987;1:89-94.
36. Spycher MO, Spath PJ. Quantification of complement receptor 1 on E; follow up of HIV-1 infected patients with AIDS-related complex and Walter-Red 5 under treatment with intravenous immunoglobulin. Vox Sang 1990;(suppl. 11):44-50.
37. Cohen JHM, Geffriaud C, Caudwell V, Kazatchkine MD. Genetic analysis of CR1 (the C3b complement receptor, CD35) expression on erythrocytes of HIV-infected individuals. AIDS 1989;3:397-9.
38. Pascual M, Danielsson C, Steiger G, Schifferli JA. Proteolytic cleavage of CR1 on human erythrocytes in vivo. Evidence for enhanced cleavage in AIDS. Eur J Immunol 1994;24:702-8.
39. Reay, P. Use of N-bromosuccinamide for the iodination of proteins for radioimmunoassay. Ann Clin Biochem 1982;19:129-33.
40. Davies KA, Peters AM, Beynon HLC, Walport MJ. Immune complex processing in systemic lupus erythematosus - in vivo imaging and clearance studies. J Clin Invest 1992;90:2075-83.
41. Hogg N, Ross GD, Jones DB, Slusarenko M, Walport MJ, Lachmann PJ. Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1). Eur J Immunol 1984;14:236-43.
42. Steinsson K, Erlendsson K, Valdimarsson H. Successful plasma infusion treatment of a patient with C2 deficiency and systemic lupus erythematosus: clinical experience over forty-five months. Arthritis Rheum 1989;32:906-13.
43. Davies KA, Erlendsson K, Beynon HLC, Peters AM, Valdimarsson H, Walport MJ. Splenic uptake of immune complexes in man is complement dependent. J Immunol 1993;151:3866-73.
44. Pepys MB. Role of complement in induction of antibody production in vivo. Effect of cobra factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses. J Exp Med 1974; 140:126-45.
45. Pryjma J, Humphrey JH. Prolonged C3 depletion by cobra venom factor in thymus-deprived mice and its implication for the role of C3 as an essential second signal for B-cell triggering. Immunology 1975;28:569-76.
46. Klaus GGB, Humphrey JH. The generation of memory cells. I. The role of C3 in the generation of B memory cells. Immunology 1977;33:31-40.
47. Hosea SW, Brown EJ, Hamburger MI, Frank MM. Opsonic requirements for intravascular clearance after splenectomy. N Engl J Med 1981;304:245-50.
48. Couser WG, Salant DJ. In-situ immune complex formation and glomerular injury. Kidney Int 1980;17:1-13.
49. Cohen MG, Li EK. Mortality in systemic lupus erythematosus: active disease is the most important factor. Aust N Z J Med 1992;22:5-8.
50. Breban M, Meyer O, Bourgeois P, Palazzo E, Kahn MF. The actuarial survival rate in systemic upus erythematosus: study of a 1976 cohort. Clin Rheumatol 1991;10: 283-8.
51. Mitchell SR, Nguyen PQ, Katz P. Increased risk of neisserial infections in systemic lupus erythematosus. Semin Arthritis Rheum 1990;20:174-84.
52. Moffit MC, Frank MM. Complement resistance in microbes. Springer Semin Immunopathol 1994;15: 327-44.
53. Vyse TJ, Späth PJ, Davies KA et al. Hereditary complement factor I deficiencies: 4 case reports and review of hereditary complement factor I, factor H and C3 deficiencies. Q J Med 1994;87:385-402.
54. Lachmann PJ. Complement deficiencies - genetic and acquired. In: Lachmann PJ, Peters DK, Rosen F, Walport MJ, eds. Clinical aspects of immunology, 5th edn. Oxford: Blackwell Scientific Publications, 1993: 1287-304.
55. Davies KA, Toothill VJ, Savill J et al. A 19-year old boy with leucocyte adhesion deficiency. In vitro and in vivo studies of leucocyte function. Clin Exp Immunol 1991; 84:223-31.
56. Davies KA, Norswrthy PJ, Loizou S, Walport MJ. Anti-C1q antibodies and SLE. Clin Exp Immunol 1994; 97:28.
57. Wisnieski JJ, Jones SM. IgG autoantibody to collagen-like region of C1q in hypocomplementemic urticarial vasculitis syndrome, systemic lupus erythematosus, and 6 other musculoskeletal or rheumatic diseases. J Rheumatol 1992;19:884-8.
58. Davies KA, Norsworthy PJ, Athanassiou P, Mason PD, Loizou S, Walport MJ. Anti-C1q antibodies in SLE. Br J Rheumatol 1994;33:96.
59. Bowness P, Davies KA, Norsworthy PJ et al. Hereditary C1q deficiency and systemic lupus erythematosus. Q J Med 1994;87:455-64.
60. Davies KA, Beynon HLC, Walport MJ. Consider prophylaxis in systemic lupus erythematosus. Br Med J 1994;308:133.
61. Tonoli M, Davies KA, Norsworthy PJ, Cohen J, Walport MJ. The anti-lipid A antibody HA-1A binds to rough Gram-negative bacteria, fixes complement and facilitates binding to erythrocyte CR1 (CD35). Clin Exp Immunol 1993;92:232-8.
62. Seelen MA, Athanassiou P, Lynn WA et al. The antilipid A monoclonal antibody E5 binds to rough Gram-negative bacteria, fixes C3, and facilitates binding of bacterial immune complexes to both erythrocytes and monocytes. Immunology 1995;84:653-61.
63. Cork CL, Morris JM, Olson JL, Krakowka S, Swift AJ, Winkelstein JA. Membranoproliferative glomerulonephritis in dogs with a genetically-determined deficiency of the third component of complement. Clin Immunol Immunopathol 1991;60:455-70.
64. Lehner PJ, Davies KA, Cope AP et al. Meningococcal septicaemia in a C6-deficient patient and effects of plasma infusion on lipopolysaccharide release. Lancet 1992;340:1379-81.
65. Kalli KR, Hsu P, Fearon DT. Therapeutic uses of recombinant complement protein inhibitors. Springer Semin Immunopathol 1994;15:417-31.
66. Beynon HLC, Davies KA, Haskard DO, Walport MJ. Erythrocytc complement receptor type 1 and interactions between immune complexes, neutrophils and endothelium. J Immunol 1994;153:3160-7.
67. Beynon HLC, Haskard DO, Davies KA, Haroutunian R, Walport MJ. Combinations of low concentrations of cytokines and acute agonists synergise in increasing the permeability of endothelial monolayers. Clin Exp Immunol 1993;91:314-9.
68. Beynon HLC, Athanassiou P, Davies KA. The endothelium in SLE and Sjögren's syndrome. In: Savage COS, Pearson JD, eds. Immunological aspects of the vascular endothelium. Cambridge University Press, 1995:124-52.
69. Davies KA, Chapman PT, Norsworthy PJ, Jamar F, Athanassiou P, Keelan ETM, Harrison AA, Binns RM, Haskard DO, Walport MJ. Clearance pathways of soluble immune complexes in the pig. Insights into the adaptive nature of antigen clearance in humans. J Immunol 1995; in press.